Research Fundamentals: Study Design, Population, and Sample Size

Umair Majid

doi:10.26685/urncst.16

PDF

Published Jan 10, 2018

DOI https://doi.org/10.26685/urncst.16

Umair Majid

URNCST Journal

Abstract

This is the second article of a three-part series that continues the discussion on the fundamentals of writing research protocols for quantitative, clinical research studies. In this editorial, the author discusses some considerations for including information in a research protocol on the study design and approach of a research study. This series provides a guide for undergraduate researchers interested in publishing their protocol in the Undergraduate Research in Natural and Clinical Sciences and Technology (URNCST) Journal.

Abstract 35219 | PDF Downloads 40622

Issue

Vol. 2 (2018): Issues 1-12 (January-December)

Section

Editorial

This work is licensed under a Creative Commons Attribution 4.0 International License.

Validation errors:

Element '{http://www.w3.org/2001/XMLSchema}include': Failed to load the document 'http://www.w3.org/Math/XMLSchema/mathml3/mathml3-common.xsd' for inclusion.

Invalid XML:

<?xml version="1.0" encoding="utf-8"?> <doi_batch xmlns="http://www.crossref.org/schema/4.3.6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" version="4.3.6" xsi:schemaLocation="http://www.crossref.org/schema/4.3.6 https://www.crossref.org/schemas/crossref4.3.6.xsd"> <head> <doi_batch_id>_1728155874</doi_batch_id> <timestamp>1728155874</timestamp> <depositor> <depositor_name>URNCST Journal</depositor_name> <email_address>editor@urncst.com</email_address> </depositor> <registrant>Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal</registrant> </head> <body> <journal> <journal_metadata> <full_title>Undergraduate Research in Natural and Clinical Science and Technology Journal</full_title> <abbrev_title>URNCST Journal</abbrev_title> <issn media_type="electronic">2561-5637</issn> </journal_metadata> <journal_issue> <publication_date media_type="online"> <month>01</month> <day>01</day> <year>2024</year> </publication_date> <journal_volume> <volume>8</volume> </journal_volume> </journal_issue> <journal_article xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" publication_type="full_text" metadata_distribution_opts="any"> <titles> <title>The Role of ICAM-1 on Immune Cells in Glioblastoma: A Literature Review</title> </titles> <contributors> <person_name contributor_role="author" sequence="first" language="en"> <given_name>Xiaoxue</given_name> <surname>Cui</surname> </person_name> </contributors> Introduction: Glioblastoma (GBM) is an extremely aggressive brain tumor that poses significant challenges to clinical oncology. Previous research has discovered that intercellular adhesion molecule-1 (ICAM-1) is expressed in immune cells and is one of the most common molecules in the tumor microenvironment. However, the entire scope of ICAM-1 functions on immune cells in glioblastoma is still under investigation. This literature review aims to synthesize existing knowledge about the role of ICAM-1 on immune cells in GBM progression. Methods: This review summarizes research from 1980-2024 using PubMed, OVID Medline, Web of Science, and Google Scholar. The following keywords were used to identify the articles focusing on the role of ICAM-1 on immune cells in glioblastoma: “glioblastoma”, “ICAM-1”, “CD54”, “macrophages”, “lymphocytes”, “dendritic cells”, and “natural killer cells”. Studies that primarily focus on ICAM-1 expression and function within the tumor microenvironment were selected. Results: Immune cell expression of ICAM-1 in the GBM microenvironment may exhibit both pro- and anti-tumor effects. In tumor-associated macrophages, ICAM-1 upregulation regulates polarization and immunosuppression. In dendritic cells, decreased ICAM-1 expression may hinder anti-tumor responses by limiting T cell activation. The role of ICAM-1 in tumor-infiltrating lymphocytes remains unclear. In neutrophils, ICAM-1 upregulation may promote immune suppression by reducing T-cell activity. The decreased ICAM-1 levels on NK cells in GBM may lead to NK cell exhaustion. Discussion: The radio-chemotherapy has differential effects on ICAM-1 functions and, to some extent, affects the interpretation of findings. In turn, the alteration of ICAM-1 expression also influences the effectiveness of GBM radio-chemotherapy and the composition of the tumor microenvironment. The corticosteroid administration and tumor types are also factors affecting immune cell activity and composition. Conclusion: This review inspires innovative therapeutic strategies to improve treatment outcomes and patient prognosis for glioblastoma, as well as provides potential directions for future research on ICAM-1 for glioblastoma. <publication_date media_type="online"> <month>07</month> <day>05</day> <year>2024</year> </publication_date> <pages> <first_page>1</first_page> <last_page>10</last_page> </pages> <ai:program xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" name="AccessIndicators"> <ai:license_ref>https://creativecommons.org/licenses/by/4.0</ai:license_ref> </ai:program> <doi_data> <doi>10.26685/urncst.626</doi> <resource>https://www.urncst.com/index.php/urncst/article/view/626</resource> <collection property="crawler-based"> <item crawler="iParadigms"> <resource>https://www.urncst.com/index.php/urncst/article/download/626/376</resource> </item> </collection> <collection property="text-mining"> <item> <resource mime_type="application/pdf">https://www.urncst.com/index.php/urncst/article/download/626/376</resource> </item> </collection> </doi_data> </journal_article> </journal> </body> </doi_batch>

##plugins.themes.bootstrap3.article.sidebar##

##plugins.themes.bootstrap3.article.main##

Abstract

##plugins.themes.bootstrap3.article.details##

Validation errors:

Invalid XML: